A clinically and functionally relevant definition of an asthma exacerbation will be invaluable in the assessment of the severity of such an event and the streamlining of the steps necessary to ...

Hospital admission was more likely among patients with acute asthma exacerbation who had lower initial EtCO2. In asthma, worse acute exacerbation outcomes may be predicted by lower end-tidal carbon ...

A link was found between gestational diabetes and increased asthma exacerbation risk during pregnancy but not postpartum. Gestational diabetes led to an increased risk for asthma exacerbations ...

Benralizumab is effective in treating eosinophilic exacerbations in patients with asthma or chronic obstructive pulmonary disease (COPD), according to study findings published in The Lancet ...

GDM increases asthma risks during pregnancy, urging early screening and improved care for better maternal outcomes.

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

We investigated the association between use of hormonal contraceptives and risk of severe asthma exacerbation in reproductive-age women with asthma. Methods We used the Optimum Patient Care Research ...

University of Virginia Asthma and Allergic Diseases Center, Department of Pediatrics, P.O. Box 800386, Charlottesville, VA 22908-0386, United States ...

Background The natural history and time course of the onset of exacerbation events of chronic obstructive pulmonary disease (COPD) is incompletely understood. Methods A prospective cohort of 212 ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

An estimated 136 million asthma exacerbations occur globally each year, 10 million of those in the US. Physically threatening and emotionally significant for patients, such exacerbations can be fatal.

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...